Maravai LifeSciences Holdings, Inc. (MRVI) AI Stock Analysis

Maravai LifeSciences Holdings, Inc. provides products essential for biopharmaceutical development, enabling drug therapies, diagnostics, and vaccines. Headquartered in San Diego, California, the company operates via two primary segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures reagents, messenger RNA, oligonucleotides, and proprietary CleanCap capping technology for gene therapy and diagnostics. The Biologics Safety Testing segment supplies analytical products for biologic manufacturing, including custom antibody and assay development, host cell protein ELISA kits, and bioprocess impurity detection products. Its customers include biopharmaceutical companies, research organizations, academic institutions, and diagnostic firms.

Maravai's revenue peaked at $883.0M in FY2022 before dropping 67.3% to $288.9M in FY2023, 10.3% to $259.2M in FY2024, and 28.3% to $185.7M in FY2025. This drove a 5-year revenue CAGR of -8.1% from FY2020 to FY2025. Gross margin contracted from 82.4% in FY2021 to 18.0% in FY2025, while operating margin fell from 69.4% to -3.6%. Net income reached -$130.8M in FY2025 with an EPS of -$0.28. Over the trailing twelve months, revenue was $208.8M with an EPS of -$0.53. In the latest quarter ended June 30, 2026, revenue increased 8.5% year-over-year, while quarterly earnings declined 32.7%.

As of June 30, 2026, Maravai held $70.1M in cash and short-term investments against total debt of $176.7M, leaving net debt at $106.6M. Shareholders' equity stood at $204.6M, representing a debt-to-equity ratio of 0.86, alongside a current ratio of 4.05 and total assets of $603.7M. For FY2025, operating cash flow turned negative at -$57.6M, free cash flow was -$70.7M, and capital expenditures were $13.1M. The company's share count increased 21.3% over five years.

Maravai trades at an enterprise value of $1.20B and a market cap of $2.51B. Its forward P/E of 370.4x stands well above the 17.3x median of its US-listed Healthcare peers. The company's price-to-sales ratio is 12.0x, compared to the peer median of 4.1x, while its EV-to-EBITDA multiple is 1.8x versus 12.0x for peers. Over the past year, the stock returned 94.6%, outpacing the S&P 500 (SPY) return of 16.8%, but its 5-year return of -81.7% lagged the S&P 500 return of 83.0%.

Wall Street coverage consists of 5 Strong Buy and 4 Hold ratings, with no Buy, Sell, or Strong Sell recommendations. The mean price target of $8.50 represents a 25.2% premium over the last close of $6.79. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $211.8M and an EPS of -$0.11. For the next fiscal year, 9 analysts project revenue of $224.9M and EPS of -$0.10. Maravai beat EPS estimates in 2 of the last 4 quarters, with next earnings scheduled for November 4, 2026.

This page is an AI-written research summary of Maravai LifeSciences Holdings, Inc. (MRVI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MRVI income statement, MRVI balance sheet, MRVI key metrics, MRVI analyst forecast, MRVI chart. See the MRVI stock overview for the latest quote and news.